Central Square Management’s Harvard Bioscience HBIO Stock Holding History

Central Square Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-2,698	Closed	-$123K	–	44
2014 Q2	$123K	Sell	2,698 -6,911	-72%	-$290K	0.13%	36
2014 Q1	$455K	Sell	9,609 -3,288	-25%	-$150K	0.43%	34
2013 Q4	$606K	Sell	12,897 -13,220	-51%	-$577K	0.48%	32
2013 Q3	$1.04M	Sell	26,117 -11,148	-30%	-$438K	0.68%	35
2013 Q2	$1.33M	Buy	+37,265	New	+$1.43M	1.1%	26

Other funds holding HBIO

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HSA

Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Central Square Management's HBIO Position: Q3 2014 in Review

Central Square Management sold out of Harvard Bioscience (HBIO) in Q3 2014, closing a stake of 2,698 shares — an estimated $123K sold.

Central Square Management first reported a position in HBIO in Q2 2013 and held it in 5 quarters. The position peaked at $1.33M in Q2 2013. 72 funds tracked by Wall St. Rank hold HBIO as of Q3 2014.

Central Square Management reported no remaining Harvard Bioscience position as of Q3 2014 after selling out during the quarter.
Central Square Management sold 2,698 Harvard Bioscience shares in Q3 2014, an estimated $123K.
Central Square Management first reported a position in Harvard Bioscience in Q2 2013 and held it in 5 quarters.
Central Square Management's Harvard Bioscience position peaked at $1.33M in Q2 2013.
72 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2014.

Based on Central Square Management's 13F filing for Q3 2014, filed 13 Nov 2014.